Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 29,594,760
  • Shares Outstanding, K 224,560
  • Annual Sales, $ 3,084 M
  • Annual Income, $ 399,000 K
  • 36-Month Beta 1.39
  • Price/Sales 9.45
  • Price/Cash Flow 21.62
  • Price/Book 3.29

Price Performance

See More
Period Period Low Period High Performance
1-Month
117.17 +10.59%
on 07/06/17
132.22 -2.00%
on 07/24/17
+3.51 (+2.78%)
since 06/23/17
3-Month
96.18 +34.73%
on 05/26/17
133.67 -3.06%
on 05/02/17
+9.03 (+7.49%)
since 04/25/17
52-Week
96.18 +34.73%
on 05/26/17
145.41 -10.89%
on 11/04/16
+2.12 (+1.66%)
since 07/25/16

Most Recent Stories

More News
Can Intercept (ICPT) Beat Estimates this Earnings Season?

Intercept Pharmaceuticals, Inc.'s (ICPT) lead drug Ocaliva's uptake has been encouraging and we expect the company to throw light on its label expansion when it reports second-quarter results.

VRTX : 163.29 (-1.70%)
GILD : 74.15 (-0.32%)
ICPT : 129.15 (+0.55%)
ALXN : 129.88 (-0.66%)
What's in the Cards for Exelixis (EXEL) in Q2 Earnings?

Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.

VRTX : 163.29 (-1.70%)
EXEL : 27.65 (-1.64%)
BMY : 56.00 (+0.72%)
ALXN : 129.88 (-0.66%)
Is Celgene (CELG) Poised For a Beat This Earnings Season?

Celgene Corporation (CELG) is likely to beat on earnings estimates when it reports results on July 27 on the back of growth in Revlimid driven by share gains in important markets.

AGIO : 58.50 (-1.48%)
CELG : 136.88 (-0.70%)
VRTX : 163.29 (-1.70%)
ALXN : 129.88 (-0.66%)
22.4% Return Seen to Date on SmarTrend Alexion Pharm Call (ALXN)

SmarTrend identified an Uptrend for Alexion Pharm (NASDAQ:ALXN) on June 12th, 2017 at $106.88. In approximately 1 month, Alexion Pharm has returned 22.41% as of today's recent price of $130.83.

ALXN : 129.88 (-0.66%)
Are Options Traders Betting on a Big Move in Alexion Pharmaceuticals (ALXN) Stock?

Investors in Alexion Pharmaceuticals, Inc. (ALXN) need to pay close attention to the stock based on moves in the options market lately.

ALXN : 129.88 (-0.66%)
Is a Beat in Store for Alexion (ALXN) this Earnings Season?

Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.

AGEN : 5.09 (-5.21%)
GILD : 74.15 (-0.32%)
ICPT : 129.15 (+0.55%)
ALXN : 129.88 (-0.66%)
Is Gilead (GILD) Poised for a Beat This Earnings Season?

Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.

VRTX : 163.29 (-1.70%)
ABBV : 72.71 (-1.62%)
GILD : 74.15 (-0.32%)
ALXN : 129.88 (-0.66%)
Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs

Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.

SRPT : 42.81 (-2.59%)
PBYI : 96.60 (+0.78%)
VRTX : 163.29 (-1.70%)
GILD : 74.15 (-0.32%)
AMGN : 180.95 (-0.06%)
ALXN : 129.88 (-0.66%)
BIIB : 283.88 (-0.29%)
5 Top Multibagger Biotech Stocks to Buy in the 2nd Half

Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.

ENZ : 11.24 (-0.53%)
ALIM : 1.46 (unch)
CELG : 136.88 (-0.70%)
EXAS : 37.75 (-4.28%)
SRPT : 42.81 (-2.59%)
VRTX : 163.29 (-1.70%)
REGN : 514.36 (-1.32%)
KITE : 111.27 (-1.51%)
ALXN : 129.88 (-0.66%)
Alexion Reportedly Being Investigated by HHS, Shares Slip

Shares of Alexion Pharmaceuticals, Inc. (ALXN) were down more than 3% on Thursday after a Bloomberg report stated that it is under investigation by the U.S. Department of Health and Human Services' (HHS)...

ENZ : 11.24 (-0.53%)
AGEN : 5.09 (-5.21%)
ADRO : 13.80 (-1.08%)
ALXN : 129.88 (-0.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system...

See More

Support & Resistance

2nd Resistance Point 133.08
1st Resistance Point 131.91
Last Price 129.88
1st Support Level 129.88
2nd Support Level 129.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.